Baird upgraded McKesson (NYSE:MCK) to outperform from neutral on Thursday, citing the updates the medical distributor gave with its Q2 FY25 financials regarding its recent deal to acquire the ...
In a report released today, Stephanie Davis from Barclays maintained a Buy rating on McKesson (MCK – Research Report), with a price target of $668.00. The company’s shares closed yesterday at ...